Displaying 1 - 12 of 15
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Displaying 1 - 12 of 15